The presence of the MT-KRAS was more frequent in N positive tumours (54.1%) (P=0.04), tumours with poor grade of differentiation (65.8%) (P=0.02), and mucinous tumours (73.8%) (p < 0.001). This evidence concerns the gene KRAS and mucinous neoplasm.